Immunohistochemical Expression of Survivin and Its Relationship with Cell Apoptosis and Proliferation in Ameloblastomas

Table 2

Average percentages of Ki-67 and nuclear Survivin expression according to ameloblastic histological types and subtypes.

Histological type	Number of cases	Mean ± SD
		%Ki-67	%Nuclear Survivin
Solid/multicystic	38	12.8 ± 10.4	0.45 ± 1.3
FSA	6	11.1 ± 6	—
ASA	10	9.9 ± 7.4	—
PSA	22	14.6 ± 14.3	0.77 ± 1.7
Unicystic	72	16.4 ± 14.3	0.72 ± 1.5
LUA	8	24.1 ± 17.8	0.5 ± 1.4
MUA	24	17.1 ± 17.8	0.67 ± 1.7
IUA	40	14.5 ± 10.9	0.8 ± 1.6

FSA: follicular solid/multicystic ameloblastoma, ASA: acanthomatous solid/multicystic ameloblastoma, PSA: plexiform solid/multicystic ameloblastoma, LUA: luminal unicystic ameloblastoma, MUA: mural unicystic ameloblastoma, IUA: intraluminal unicystic ameloblastoma. Kruskal-Wallis test. No statistical significance was observed between Ki-67 and Nuclear Survivin, in subtypes of ameloblastomas.